PCL, Inc. (KOSDAQ:241820)

Market Cap	17.87B
Revenue (ttm)	4.98B
Net Income (ttm)	-47.06B
Shares Out	2.96M
EPS (ttm)	-14,020.37
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,872
Average Volume	45,771
Open	6,140.00
Previous Close	6,140.00
Day's Range	6,000.00 - 6,140.00
52-Week Range	5,900.00 - 43,800.00
Beta	1.97
RSI	24.19
Earnings Date	Nov 11, 2025

About PCL, Inc.

PCL, Inc. provides multiplex in vitro diagnostic (IVD) products and platform services. The company offers HiSU solution, an automated multi-immune diagnostic system that performs various diagnostics, high-speed tests including blood screening, multiple cancer screening, autoimmune testing, etc. It also provides antigen and antibody diagnostic kits, including PCLOK II anti-HIV/HCV/syphilis, and PCLOK II HBsAg/HIV p24. In addition, the company offers platform services, such as SG ID for identifying novel target substances. Further, it offers covi...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2008
• Employees: 31
• Stock Exchange: KOSDAQ
• Ticker Symbol: 241820

Financial Performance

In 2024, PCL, Inc.'s revenue was 1.25 billion, a decrease of -85.22% compared to the previous year's 8.43 billion. Losses were -52.34 billion, 157.6% more than in 2023.